GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

The asset in question is GSK’s 72.5% stake in its Indian subsidiary GlaxoSmithKline Consumer Healthcare, famous for the malted ... healthcare nutrition products in March this year.

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

The Nigerian economy has seen the closure of many companies, especially multinational firms, which threw many Nigerians into ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.

GlaxoSmithKline (GSK) is a global biopharmaceutical company that focuses on the development and marketing of medicines, vaccines, and healthcare products, with a strong emphasis on innovation in ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn ... reflecting strong performance of new products and the investment we've put ...